Quarterly report pursuant to Section 13 or 15(d)

Revenue

v3.7.0.1
Revenue
6 Months Ended
Jun. 30, 2017
Revenue  
Revenue

 

Note 3 — Revenue

 

The revenue recognized to date relates to the upfront fee and non-substantive development milestone payments received under the GSK Collaboration and License Agreement, which are being recognized in revenue using the proportional performance model systematically over the period in which the Company is delivering services under the GSK Collaboration and License Agreement, which is determined to be the period until GSK’s option to obtain licenses expires.